Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4632584 | 1.00 | NPC1 (0.32) | NPC1RAB9AKMT2AHPGDTSHR | |
| Hydrochloric Acid SCHEMBL19307239 | 0.88 | — | — | |
| SCHEMBL19305204 | 0.81 | NPC1 (0.33) | NPC1RAB9AKMT2AHPGDTSHR | |
| SCHEMBL16862855 | 0.81 | NPC1 (0.33) | NPC1RAB9AKMT2AHPGDTSHR | |
| Hydrochloric Acid SCHEMBL1653766 | 0.78 | MAPT (0.43) | HPGD | |
| SCHEMBL995991 | 0.78 | NPC1 (0.33) | NPC1RAB9AKMT2AHPGDTSHR | |
| Hydrochloric Acid SCHEMBL2064723 | 0.77 | POLB (0.37) | HPGDTSHR | |
| Hydrochloric Acid SCHEMBL175377 | 0.77 | POLB (0.37) | HPGDTSHR | |
| Hydrochloric Acid SCHEMBL4119676 | 0.75 | POLB (0.38) | HPGDTSHR | |
| Hydrochloric Acid SCHEMBL9996099 | 0.75 | POLB (0.38) | NPC1RAB9AKMT2AHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10384987-B2 | 1,3-butadiene synthesis | ARLANXEO DEUTSCHLAND GMBH (DE) | 2019-08-20 | — | — | US | claimed |
| US-20170327436-A1 | 1,3-BUTADIENE SYNTHESIS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2017-11-16 | — | — | US | claimed |
| US-8981082-B2 | Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435 | Janssen Pharmaceuticals, Inc. (US) | 2015-03-17 | — | — | US | claimed |
| US-20140235852-A1 | PROCESS FOR PREPARING AN INTERMEDIATE OF THE MACROCYCLIC PROTEASE INHIBITOR TMC 435 | Janssen Pharmaceuticals, Inc. (US) | 2014-08-21 | — | — | US | claimed |
| US-8461223-B2 | Microporous polycyclopentadiene-based aerogels | ASPEN AEROGELS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| WO-2006110471-A2 | MICROPOROUS POLYDICYCLOPENDIENE-BASED AEROGELS | ASPEN AEROGELS, INC. (US) | 2006-10-19 | — | — | WO | claimed |
| US-20060229374-A1 | MICROPOROUS POLYDICYCLOPENDIENE-BASED AEROGELS | MIDCAP FUNDING IV TRUST | 2006-10-12 | — | — | US | claimed |
| US-10384987-B2 | 1,3-butadiene synthesis | ARLANXEO DEUTSCHLAND GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| US-9856265-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-02 | — | — | US | disclosed |
| US-20170327436-A1 | 1,3-BUTADIENE SYNTHESIS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
| US-20170226307-A1 | MICROPOROUS POLYOLEFIN-BASED AEROGELS | ASPEN AEROGELS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| WO-2017064680-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SIMEPREVIR SODIUM AND INTERMEDIATE THEREOF | LUPIN LIMITED (IN) | 2017-04-20 | — | — | WO | disclosed |
| WO-2007014925-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014920-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014918-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014923-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014921-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014922-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| US-20060229374-A1 | MICROPOROUS POLYDICYCLOPENDIENE-BASED AEROGELS | MIDCAP FUNDING IV TRUST | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | NPC1 514/4885RAB9A 2446/4885KMT2A 3645/4885 |
| US-10384987-B2 | 1,3-butadiene synthesis | SQLE, FDFT1, ENO1 | NPC1 1840/4885RAB9A 3303/4885KMT2A 3912/4885 |
| US-20170327436-A1 | 1,3-BUTADIENE SYNTHESIS | SQLE, FDFT1, ENO1 | NPC1 1840/4885RAB9A 3303/4885KMT2A 3912/4885 |
| US-20140235852-A1 | PROCESS FOR PREPARING AN INTERMEDIATE OF THE MACROCYCLIC PROTEASE INHIBITOR TMC 435 | CTRC, GTF3C4, CTSC | NPC1 970/4885RAB9A 2337/4885KMT2A 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.